Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Variant||ETV6 - JAK3|
|Protein Effect||gain of function|
|Gene Variant Descriptions||ETV6-JAK3 results from the fusion of ETV6 and JAK3, which leads to constitutive activation of Stat1 and Stat3, increased expression of Stat5 target genes, and is transforming in cell culture (PMID: 10706877).|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ETV6 - JAK3||hematologic cancer||predicted - resistant||Ilginatinib||Preclinical - Cell culture||Actionable||In a preclinical study, cells expressing ETV6-JAK3 were insensitive to treatment with NS-108 in culture (PMID: 22829185).||22829185|
|ETV6 - JAK3||hematologic cancer||sensitive||Pyridone 6||Preclinical - Cell culture||Actionable||In a preclinical study, Pyridone 6 (CMP6) inhibited proliferation of transformed cells expressing ETV6-JAK3 in culture (PMID: 23471820).||23471820|
|Molecular Profile||Protein Effect||Treatment Approaches|
|ETV6 - JAK3||gain of function|